Examining the number of interactions between the genes associated with depression and the second level ATC drug classifications demonstrates that there are currently available pharmaceutical treatments that may target the genetic component of depression. Most notable were the large number of interactions between the DRD2 gene and the N05 drug classification, which primarily comprises typical and atypical antipsychotics. The dopaminergic system has been previously implicated in depression, particularly the symptoms of anhedonia and decreased motivation, and antidepressant action has been reported for dopamine reuptake inhibitors and D2-receptor agonists in animal models of depression 44. Furthermore, the dopamine and noradrenaline reuptake inhibitor bupropion is licensed for the treatment of depression.
